Home/Filings/4/0001440766-11-000003
4//SEC Filing

Dingivan Christine A 4

Accession 0001440766-11-000003

CIK 0001003124other

Filed

Dec 5, 7:00 PM ET

Accepted

Dec 6, 9:09 AM ET

Size

22.8 KB

Accession

0001440766-11-000003

Insider Transaction Report

Form 4
Period: 2011-12-05
Dingivan Christine A
EVP/Chief Medical Officer
Transactions
  • Disposition to Issuer

    Stock Option (to buy)

    2011-12-0520,0000 total
    Exercise: $26.64Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0593,1560 total
    Exercise: $36.65Common Stock (93,156 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-057,7630 total
    Exercise: $19.94Common Stock (7,763 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2011-12-0515,0000 total
    Common Stock (15,000 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-057,7630 total
    Exercise: $37.69Common Stock (7,763 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0545,0000 total
    Exercise: $27.27Common Stock (45,000 underlying)
  • Disposition to Issuer

    Stock Option (to buy)

    2011-12-0541,4030 total
    Exercise: $20.45Common Stock (41,403 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0531,0520 total
    Exercise: $25.74Common Stock (31,052 underlying)
Footnotes (6)
  • [F1]The stock options were cancelled pursuant to the Agreement and Plan of Merger (the "Agreement") by and among Pharmaceutical Product Development, Inc., Jaguar Holdings, LLC and Jaguar Merger Sub, Inc. dated as of October 2, 2011, on the effective date of the merger contemplated by the Agreement (the "Merger") in exchange for a cash payment equal to the difference (if any ) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/23/12, 2/23/13 and 2/23/14 but vesting was accelerated due to the Merger.
  • [F2]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 6/17/11, 6/17/12 and 6/17/13 but vesting was accelerated due to the Merger.
  • [F3]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/25/11, 2/25/12 and 2/25/13 but vesting was accelerated due to the Merger.
  • [F4]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/18/10, 2/18/11 and 2/18/12 but vesting was accelerated due to the Merger.
  • [F5]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes.
  • [F6]Each restricted stock unit (RSU) represents a contingent right to receive one share of PPDI common stock. The RSUs were scheduled to vest in three equal increments on 2/23/12, 2/23/13 and 2/23/14 but became fully vested pursuant to the terms of the Agreement. The RSUs were disposed of pursuant to the terms of the Agreement in exchange for a cash payment of $33.25 per share upon the effective date of the Merger.

Issuer

PHARMACEUTICAL PRODUCT DEVELOPMENT INC

CIK 0001003124

Entity typeother

Related Parties

1
  • filerCIK 0001440766

Filing Metadata

Form type
4
Filed
Dec 5, 7:00 PM ET
Accepted
Dec 6, 9:09 AM ET
Size
22.8 KB